Phenotypic and genotypic spectrum of congenital disorders of glycosylation type I and type II.

[1]  C. Barba,et al.  Congenital disorders of glycosylation presenting as epileptic encephalopathy with migrating partial seizures in infancy , 2016, Developmental medicine and child neurology.

[2]  G. Matthijs,et al.  ALG3‐CDG: Report of two siblings with antenatal features carrying homozygous p.Gly96Arg mutation , 2015, American journal of medical genetics. Part A.

[3]  Susan Sparks,et al.  PMM2-CDG (CDG-Ia) , 2015 .

[4]  A. Nordgren,et al.  A novel phenotype in N-glycosylation disorders: Gillessen-Kaesbach–Nishimura skeletal dysplasia due to pathogenic variants in ALG9 , 2015, European Journal of Human Genetics.

[5]  W. Dobyns,et al.  ATP6V0A2-Related Cutis Laxa , 2015 .

[6]  L. de Meirleir,et al.  ALG11-CDG: Three novel mutations and further characterization of the phenotype , 2014, Molecular genetics and metabolism reports.

[7]  M. Venturini,et al.  Identification of two novel ATP6V0A2 mutations in an infant with cutis laxa by exome sequencing. , 2014, Journal of dermatological science.

[8]  M. Simon,et al.  Topographical and nano-mechanical characterization of native corneocytes using atomic force microscopy. , 2014, Journal of dermatological science.

[9]  T. Gadomski,et al.  Congenital disorders of glycosylation: new defects and still counting , 2014, Journal of Inherited Metabolic Disease.

[10]  H. Freeze,et al.  ATP6V0A2 mutations present in two Mexican Mestizo children with an autosomal recessive cutis laxa syndrome type IIA , 2014, Molecular genetics and metabolism reports.

[11]  D. Krasnewich,et al.  Congenital Disorders of N-linked Glycosylation Pathway Overview , 2014 .

[12]  G. Matthijs,et al.  ALG3-CDG (CDG-Id): clinical, biochemical and molecular findings in two siblings. , 2013, Molecular genetics and metabolism.

[13]  S. Mundlos,et al.  Further characterization of ATP6V0A2-related autosomal recessive cutis laxa , 2012, Human Genetics.

[14]  K. Adeli,et al.  Closing the gaps in pediatric laboratory reference intervals: a CALIPER database of 40 biochemical markers in a healthy and multiethnic population of children. , 2012, Clinical chemistry.

[15]  G. Matthijs,et al.  Improved diagnostics lead to identification of three new patients with congenital disorder of glycosylation‐Ip , 2012, Human mutation.

[16]  H. Gröne,et al.  Successful prenatal mannose treatment for congenital disorder of glycosylation-Ia in mice , 2011, Nature Medicine.

[17]  E. Morava,et al.  Congenital disorders of glycosylation: sweet news , 2011, Current opinion in pediatrics.

[18]  E. Morava,et al.  How to find and diagnose a CDG due to defective N-glycosylation , 2011, Journal of Inherited Metabolic Disease.

[19]  C. Pérez-Cerdá,et al.  Expression analysis revealing destabilizing mutations in phosphomannomutase 2 deficiency (PMM2-CDG) , 2011, Journal of Inherited Metabolic Disease.

[20]  C. Thiel,et al.  A severe human metabolic disease caused by deficiency of the endoplasmatic mannosyltransferase hALG11 leads to congenital disorder of glycosylation-Ip. , 2010, Human molecular genetics.

[21]  G. Matthijs,et al.  Quality control of glycoproteins bearing truncated glycans in an ALG9-defective (CDG-IL) patient. , 2009, Glycobiology.

[22]  B. Fernandez,et al.  Loss-of-function mutations in ATP6V0A2 impair vesicular trafficking, tropoelastin secretion and cell survival. , 2009, Human molecular genetics.

[23]  A. Superti-Furga,et al.  Congenital disorder of glycosylation type Id (CDG Id): phenotypic, biochemical and molecular characterization of a new patient , 2008, Journal of Inherited Metabolic Disease.

[24]  E. Hoppenreijs,et al.  Pericardial and abdominal fluid accumulation in congenital disorder of glycosylation type Ia. , 2008, Molecular genetics and metabolism.

[25]  G. Matthijs,et al.  Cerebellar ataxia and congenital disorder of glycosylation Ia (CDG-Ia) with normal routine CDG screening , 2007, Journal of Neurology.

[26]  H. Freeze,et al.  CDG‐Id in two siblings with partially different phenotypes , 2007, American journal of medical genetics. Part A.

[27]  J. Denecke,et al.  Congenital Disorder of Glycosylation Type Id: Clinical Phenotype, Molecular Analysis, Prenatal Diagnosis, and Glycosylation of Fetal Proteins , 2005, Pediatric Research.

[28]  T. Hennet,et al.  CDG‐IL: An infant with a novel mutation in the ALG9 gene and additional phenotypic features , 2005, American journal of medical genetics. Part A.

[29]  W. Chung,et al.  Congenital disorder of glycosylation id presenting with hyperinsulinemic hypoglycemia and islet cell hyperplasia. , 2005, The Journal of clinical endocrinology and metabolism.

[30]  G. Matthijs,et al.  CDG-Id caused by homozygosity for an ALG3 mutation due to segmental maternal isodisomy UPD3(q21.3-qter). , 2005, European journal of medical genetics.

[31]  R. Wevers,et al.  Defective protein glycosylation in patients with cutis laxa syndrome , 2005, European Journal of Human Genetics.

[32]  J. Jeppsson,et al.  Improved HPLC method for carbohydrate-deficient transferrin in serum. , 2003, Clinical chemistry.

[33]  I. Yuasa,et al.  Novel nonsense mutation (R194X) in the PMM2 gene in a Japanese patient with congenital disorder of glycosylation type Ia , 2003, Brain & development (Tokyo. 1979).

[34]  H. Freeze,et al.  A mutation in the human MPDU1 gene causes congenital disorder of glycosylation type If (CDG-If). , 2001, The Journal of clinical investigation.

[35]  G. Raymond,et al.  MPDU1 mutations underlie a novel human congenital disorder of glycosylation, designated type If. , 2001, The Journal of clinical investigation.

[36]  E. Schaftingen,et al.  High residual activity of PMM2 in patients' fibroblasts: possible pitfall in the diagnosis of CDG-Ia (phosphomannomutase deficiency). , 2001, American journal of human genetics.

[37]  H. Freeze,et al.  Mutations in PMM2 that cause congenital disorders of glycosylation, type Ia (CDG‐Ia) , 2000, Human mutation.

[38]  K. Shigemoto,et al.  Missense mutations in the phosphomannomutase 2 gene of two Japanese siblings with carbohydrate-deficient glycoprotein syndrome type I , 1999, Brain and Development.

[39]  U. Stephani,et al.  Carbohydrate-Deficient Glycoprotein Syndrome - A Fourth Subtype , 1995, Neuropediatrics.

[40]  Ajit Varki,et al.  Oligosaccharides in vertebrate development , 1995 .

[41]  J. Jaeken,et al.  Carbohydrate deficient serum transferrin in a new systemic hereditary syndrome. , 1990, Archives of disease in childhood.

[42]  H. G. Eijk,et al.  Sialic acid-deficient serum and cerebrospinal fluid transferrin in a newly recognized genetic syndrome. , 1984, Clinica chimica acta; international journal of clinical chemistry.

[43]  F. Alkuraya,et al.  Further Delineation of the ALG9-CDG Phenotype. , 2016, JIMD reports.

[44]  J. Jaeken.  Congenital disorders of glycosylation. , 2013, Handbook of clinical neurology.

[45]  C. Speck-Martins,et al.  Clinical and Molecular Features of Patients with Congenital Disorders of Glycosylation in Brazil , 2013 .

[46]  D. Babovic‐Vuksanovic,et al.  Laboratory Diagnosis of Congenital Disorders of Glycosylation Type I by Analysis of Transferrin Glycoforms , 2012, Molecular Diagnosis & Therapy.

[47]  S. Grünewald,et al.  The clinical spectrum of phosphomannomutase 2 deficiency (CDG-Ia). , 2009, Biochimica et biophysica acta.

[48]  H. Brunner,et al.  Defining the phenotype in an autosomal recessive cutis laxa syndrome with a combined congenital defect of glycosylation , 2008, European Journal of Human Genetics.

[49]  J. Jaeken,et al.  Diagnosis of congenital disorders of glycosylation by capillary zone electrophoresis of serum transferrin. , 2004, Clinical chemistry.

[50]  Identification and Functional Analysis of a Defect in the Human ALG9 Gene: Definition of Congenital Disorder of Glycosylation Type I L , 2022 .